@jeffmarc

Wegovy can be prescribed to patients who are just overweight if they have risk for cardiac disease. It is approved for that cohort of patients since it lowers risk for cardiac event via lowering inflammatory processes in the body.

Also, since PC is driven by increased BMI it can theoretically slow its progression. There are some preliminary studies done that showed better response to RT and chemo for cancer patients in general who were using GLPs - those are retrospective studies, so now they will start doing real randomized studies to see is that observation holds.